Aktis Oncology (NASDAQ:AKTS) Shares Down 8.3% – What’s Next?

Aktis Oncology (NASDAQ:AKTS)’s stock price was down 8.3% during mid-day trading on Monday. The company traded as low as $14.89 and last traded at $14.6060. Approximately 57,666 shares traded hands during trading, a decline of 84% from the average daily volume of 349,898 shares. The stock had previously closed at $15.93.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on AKTS. Wedbush reaffirmed an “outperform” rating and set a $35.00 target price on shares of Aktis Oncology in a report on Friday, October 2nd. Wall Street Zen cut Aktis Oncology from a “hold” rating to a “sell” rating in a research note on Saturday, July 25th. Oppenheimer assumed coverage on Aktis Oncology in a research report on Wednesday, September 9th. They set an “outperform” rating and a $40.00 price target on the stock. BMO Capital Markets initiated coverage on Aktis Oncology in a research note on Tuesday, August 18th. They set an “outperform” rating and a $37.00 price objective on the stock. Finally, Weiss Ratings cut Aktis Oncology from a “sell (d+)” rating to a “sell (d)” rating in a report on Friday, October 2nd. One analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Aktis Oncology currently has an average rating of “Moderate Buy” and a consensus price target of $35.62.

Aktis Oncology Trading Up 2.4%

The stock’s fifty day moving average price is $20.16 and its two-hundred day moving average price is $20.97.

Aktis Oncology (NASDAQ:AKTS) last announced its quarterly earnings data on Thursday, August 13th. The technology company reported ($0.44) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.01). The company had revenue of $3.38 million for the quarter, compared to analyst estimates of $2.70 million. On average, research analysts forecast that Aktis Oncology will post -1.84 earnings per share for the current year.

Institutional Trading of Aktis Oncology

Several large investors have recently bought and sold shares of the business. GK Wealth Management LLC acquired a new position in Aktis Oncology during the third quarter worth about $26,000. State of Wyoming acquired a new stake in shares of Aktis Oncology in the 2nd quarter valued at approximately $32,000. AXQ Capital LP bought a new stake in shares of Aktis Oncology during the 2nd quarter valued at approximately $226,000. Susquehanna International Group LLP bought a new stake in shares of Aktis Oncology during the 2nd quarter valued at approximately $278,000. Finally, Deutsche Bank AG increased its position in Aktis Oncology by 49.3% during the 2nd quarter. Deutsche Bank AG now owns 21,022 shares of the technology company’s stock worth $678,000 after purchasing an additional 6,942 shares in the last quarter. 28.84% of the stock is owned by institutional investors and hedge funds.

Aktis Oncology Company Profile

Aktis Oncology, Inc is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies for the treatment of cancer. The company’s research is directed primarily toward therapies for solid tumors, an area where it seeks to improve the ability of the immune system to recognize and eliminate cancer cells.

Aktis Oncology is developing a pipeline of targeted oncology candidates based on proprietary immune-cell engagement technologies. These therapies are intended to direct immune cells toward tumor-associated targets and potentially address cancers that are difficult to treat with existing immunotherapies.

The company’s programs remain in development, and publicly available information about its commercial products, geographic operations, and leadership is limited.